Will Pfizer's good second-quarter keep it in the top spot?
This article was originally published in Scrip
Executive Summary
Pfizer's positive second-quarter results have surprised many figures in the industry, including Credit Suisse analysts who predicted EPS of $0.49, $0.06 below the company's adjusted diluted EPS.